Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

NCT03350815 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

322

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: 150 mg open-label secukinumab
DRUG: 150 mg double-blinded secukinumab
DRUG: 300 mg double-blinded secukinumab

Sponsor

Novartis Pharmaceuticals